The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.

@article{Hiatt2013TheCS,
  title={The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.},
  author={William Robert Hiatt and Sanjay Kaul and Robert J. Smith},
  journal={The New England journal of medicine},
  year={2013},
  volume={369 14},
  pages={1285-7}
}
n engl j med nejm.org 1 Administration (FDA) considers a decrease in glycated hemoglobin an approvable end point, very intensive glycemic control is associated with increased cardiovascular and all-cause mortality.1 The safety of specific drugs for type 2 diabetes — particularly the thiazolidinediones — has also been questioned. After rosiglitazone had been approved in the United States in 1999 and in Europe in 2000, a highly publicized metaanalysis in 2007 reported a 43% increase in myocardial… CONTINUE READING
58 Citations
4 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 58 extracted citations

Similar Papers

Loading similar papers…